Valion Bio (VBIO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
VBIO slides 4.9% to $1.17, a 52-week low, 6 down days in a row. Closed at $1.17, -4.88% vs the prior close of $1.23. Day range $1.13–$1.24, opened at $1.23.
VBIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — VBIO slides 4.9% to $1.17, a 52-week low, 6 down days in a row
- Closed at $1.17, -4.88% vs the prior close of $1.23. Day range $1.13–$1.24, opened at $1.23.
- Volume was 268.44K shares, 0.1x its 50-day average of 2.14M — lighter than usual.
- Price is -62.1% vs its 50-day average ($3.09) and -93.0% vs its 200-day average ($16.77).
- 52-week range $1.11–$75.50; today's close sits at 0% of that range, 98.5% below the 52-week high.
- That makes 6 straight losses.
Oct 15, 2026 — VBIO slides 15.2% to $1.23, a 52-week low on 7.3x normal volume
- Closed at $1.23, -15.17% vs the prior close of $1.45. Day range $1.11–$1.33, opened at $1.11.
- Volume was 13.56M shares, 7.3x its 50-day average of 1.87M — unusually heavy trading.
- Price is -61.6% vs its 50-day average ($3.20) and -92.7% vs its 200-day average ($16.96).
- 52-week range $1.11–$75.50; today's close sits at 0% of that range, 98.4% below the 52-week high.
- That makes 5 straight losses.
- SEC filings that day: 8-K.
Oct 14, 2026 — VBIO slides 6.5% to $1.45, a 52-week low, 4 down days in a row
- Closed at $1.45, -6.45% vs the prior close of $1.55. Day range $1.43–$1.55, opened at $1.54.
- Volume was 160.10K shares, 0.1x its 50-day average of 1.87M — lighter than usual.
- Price is -56.4% vs its 50-day average ($3.32) and -91.5% vs its 200-day average ($17.14).
- 52-week range $1.43–$76.50; today's close sits at 0% of that range, 98.1% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
Oct 13, 2026 — VBIO slides 7.7% to $1.55, a 52-week low, 3 down days in a row
- Closed at $1.55, -7.74% vs the prior close of $1.68. Day range $1.47–$1.68, opened at $1.68.
- Volume was 179.20K shares, 0.1x its 50-day average of 1.86M — lighter than usual.
- Price is -55.2% vs its 50-day average ($3.46) and -91.1% vs its 200-day average ($17.33).
- 52-week range $1.47–$76.50; today's close sits at 0% of that range, 98.0% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — VBIO slides 21.5% to $1.68, a 52-week low
- Closed at $1.68, -21.50% vs the prior close of $2.14. Day range $1.59–$2.14, opened at $2.10.
- Volume was 248.60K shares, 0.1x its 50-day average of 1.86M — lighter than usual.
- Price is -53.2% vs its 50-day average ($3.59) and -90.4% vs its 200-day average ($17.56).
- 52-week range $1.59–$76.50; today's close sits at 0% of that range, 97.8% below the 52-week high.
Oct 9, 2026 — VBIO slides 3.2% to $2.14
- Closed at $2.14, -3.17% vs the prior close of $2.21. Day range $2.10–$2.27, opened at $2.19.
- Volume was 140.00K shares, 0.1x its 50-day average of 1.86M — lighter than usual.
- Price is -42.3% vs its 50-day average ($3.71) and -88.0% vs its 200-day average ($17.79).
- 52-week range $2.05–$78.75; today's close sits at 0% of that range, 97.3% below the 52-week high.
Oct 8, 2026 — VBIO rises 0.9% to $2.21
- Closed at $2.21, +0.91% vs the prior close of $2.19. Day range $2.07–$2.28, opened at $2.07.
- Volume was 150.90K shares, 0.1x its 50-day average of 1.85M — lighter than usual.
- Price is -41.9% vs its 50-day average ($3.80) and -87.7% vs its 200-day average ($18.00).
- 52-week range $2.05–$78.75; today's close sits at 0% of that range, 97.2% below the 52-week high.
- SEC filings that day: 8-K, S-3.
Oct 7, 2026 — VBIO slides 8.0% to $2.19, 3 down days in a row
- Closed at $2.19, -7.98% vs the prior close of $2.38. Day range $2.18–$2.38, opened at $2.31.
- Volume was 125.50K shares, 0.1x its 50-day average of 1.85M — lighter than usual.
- Price is -43.8% vs its 50-day average ($3.90) and -88.0% vs its 200-day average ($18.21).
- 52-week range $2.05–$78.75; today's close sits at 0% of that range, 97.2% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — VBIO slides 4.0% to $2.38
- Closed at $2.38, -4.03% vs the prior close of $2.48. Day range $2.33–$2.48, opened at $2.36.
- Volume was 128.30K shares, 0.1x its 50-day average of 1.85M — lighter than usual.
- Price is -40.5% vs its 50-day average ($4.00) and -87.1% vs its 200-day average ($18.43).
- 52-week range $2.05–$78.75; today's close sits at 0% of that range, 97.0% below the 52-week high.
- SEC filings that day: 8-K.
Oct 5, 2026 — VBIO slides 4.2% to $2.48
- Closed at $2.48, -4.25% vs the prior close of $2.59. Day range $2.30–$2.49, opened at $2.42.
- Volume was 309.80K shares, 0.2x its 50-day average of 1.85M — lighter than usual.
- Price is -39.4% vs its 50-day average ($4.09) and -86.7% vs its 200-day average ($18.66).
- 52-week range $2.05–$78.75; today's close sits at 1% of that range, 96.9% below the 52-week high.
Oct 2, 2026 — VBIO jumps 3.2% to $2.59
- Closed at $2.59, +3.19% vs the prior close of $2.51. Day range $2.46–$2.69, opened at $2.55.
- Volume was 237.60K shares, 0.1x its 50-day average of 1.84M — lighter than usual.
- Price is -38.2% vs its 50-day average ($4.19) and -86.3% vs its 200-day average ($18.90).
- 52-week range $2.05–$78.75; today's close sits at 1% of that range, 96.7% below the 52-week high.
VBIO latest news & SEC filings
Every SEC filing by or about VBIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 16, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
Oct 8, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 2, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wolf Lisa G converted options/RSUs into 4 shares on Sep 18, 2026; now holds 29
- Wolf Lisa G had withheld for taxes 2 shares at $2.12 (≈$4) on Sep 18, 2026; now holds 27
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 17, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 17, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Things to know before you trade VBIO
- Last results release: May 14, 2026 (8-K Item 2.02). Previous ones: Mar 25, 2026, Nov 14, 2025, Aug 14, 2025. Based on that rhythm, the next report is likely around Aug 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 8.67% (largest 27.5%). That is a volatile stock.
- Liquidity: about 4.18M shares (≈$4.88M) trade per day on average.
- 52-week position: $1.17 vs a range of $1.11–$75.50 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:25 on Aug 31, 2026, 1:17 on Mar 7, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 0 sales; latest: Sheryle Bolton bought 10,000 shares on Apr 15, 2026.
- Latest filings: 8-K Oct 15, 2026; 8-K Oct 14, 2026; 8-K Oct 8, 2026.
- Share count: 22.19M shares outstanding (Aug 13, 2026), +1948.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
VBIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.23 | 1.24 | 1.13 | 1.17 | 268.44K |
| Oct 15, 2026 | 1.11 | 1.33 | 1.11 | 1.23 | 13.73M |
| Oct 14, 2026 | 1.54 | 1.55 | 1.43 | 1.45 | 160.10K |
| Oct 13, 2026 | 1.68 | 1.68 | 1.47 | 1.55 | 179.20K |
| Oct 12, 2026 | 2.10 | 2.14 | 1.59 | 1.68 | 248.60K |
| Oct 9, 2026 | 2.19 | 2.27 | 2.10 | 2.14 | 140.00K |
| Oct 8, 2026 | 2.07 | 2.28 | 2.07 | 2.21 | 150.90K |
| Oct 7, 2026 | 2.31 | 2.38 | 2.18 | 2.19 | 125.50K |
| Oct 6, 2026 | 2.36 | 2.48 | 2.33 | 2.38 | 128.30K |
| Oct 5, 2026 | 2.42 | 2.49 | 2.30 | 2.48 | 309.80K |
| Oct 2, 2026 | 2.55 | 2.69 | 2.46 | 2.59 | 237.60K |
| Oct 1, 2026 | 2.55 | 2.75 | 2.48 | 2.51 | 674.70K |
| Sep 30, 2026 | 4.00 | 4.39 | 2.53 | 2.80 | 52.29M |
| Sep 29, 2026 | 2.63 | 3.12 | 2.41 | 2.83 | 376.60K |
| Sep 28, 2026 | 2.82 | 3.03 | 2.65 | 2.70 | 219.90K |
| Sep 25, 2026 | 3.34 | 3.50 | 2.79 | 3.03 | 751.80K |
| Sep 24, 2026 | 2.62 | 3.79 | 2.32 | 3.48 | 10.75M |
| Sep 23, 2026 | 2.45 | 3.29 | 2.25 | 2.73 | 2.11M |
| Sep 22, 2026 | 2.41 | 2.80 | 2.36 | 2.49 | 536.10K |
| Sep 21, 2026 | 2.14 | 2.45 | 2.13 | 2.38 | 122.70K |
About Valion Bio
Valion Bio (VBIO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN ANTONIO, TX. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1787740.
VBIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Sheryle Bolton | Director | Apr 20, 2026 |
| Jennifer Ernst | Chief Executive Officer | Dec 22, 2025 |
| Michael K Handley | Chief Executive Officer | May 20, 2026 |
| Thomas Jensen | Director | Sep 17, 2026 |
| Jared David Malbin | Director | Sep 17, 2026 |
| Christina Rizopoulos Valauri | Director | Apr 2, 2026 |
| Dean Zikria | Interim CEO | Sep 24, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jennifer Ernst | Chief Executive Officer | Dec 22, 2025 |
| Michael K Handley | Chief Executive Officer | May 20, 2026 |
| Melinda Lackey | General Counsel & SVP of Legal | May 4, 2026 |
| Lisa G Wolf | COO & CFO | Sep 24, 2026 |
| Dean Zikria | Interim CEO | Sep 24, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 15, 2026 | Sheryle Bolton | Buy | 10,000 | $1.04 |
| Apr 15, 2026 | Sheryle Bolton | Buy | 10,000 | $1.04 |
| Apr 15, 2026 | Sheryle Bolton | Buy | 10,000 | $1.04 |
| Apr 15, 2026 | Sheryle Bolton | Buy | 10,000 | $1.04 |
| Apr 1, 2026 | Christina Rizopoulos Valauri | Buy | 19,000 | $0.95 |
| Apr 1, 2026 | Christina Rizopoulos Valauri | Buy | 19,000 | $0.95 |
| Apr 1, 2026 | Christina Rizopoulos Valauri | Buy | 19,000 | $0.95 |
| Apr 1, 2026 | Christina Rizopoulos Valauri | Buy | 19,000 | $0.95 |
VBIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-8.88M | — | $-7.00M |
| Dec 31, 2024 | $780.00K | $-5.66M | -19.68 | $-5.72M |
| Dec 31, 2023 | $1.18M | $-8.24M | -176.80 | $-8.51M |
| Dec 31, 2022 | $1.84M | $-10.10M | -104.32 | $-8.92M |
| Dec 31, 2021 | $1.26M | $-8.49M | -2.43 | $-5.61M |
Latest balance sheet: total assets $32.47M, total liabilities $20.59M, cash $2.11M (as of Jun 30, 2026).
VBIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| May 14, 2026 | 8-K Item 2.02 (results) | $23.27 |
| Mar 25, 2026 | 8-K Item 2.02 (results) | $28.50 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $47.75 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $87.50 |
| May 15, 2025 | 8-K Item 2.02 (results) | $108.00 |
| Mar 21, 2025 | 8-K Item 2.02 (results) | $88.75 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $155.98 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 25, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
| Aug 14, 2023 | 8-K Item 2.02 (results) | — |
| May 15, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on VBIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.